Meeting
2018 ASCO Annual Meeting
Safety and antitumor activity of durvalumab monotherapy in patients with pretreated extensive disease small-cell lung cancer (ED-SCLC).
Authors
Jonathan Wade Goldman
UCLA Medical Center, Los Angeles, CA
Jonathan Wade Goldman , Afshin Dowlati , Scott Joseph Antonia , John J. Nemunaitis , Marcus O. Butler , Neil Howard Segal , Pamela Ann Smith , Jared Weiss , Dan Paul Zandberg , Feng Xiao , Natasha Angra , Shaad Essa Abdullah , Shirish M. Gadgeel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Clinical Trial Registration Number
NCT01693562
Citation
J Clin Oncol 36, 2018 (suppl; abstr 8518)
DOI
10.1200/JCO.2018.36.15_suppl.8518
Abstract #
8518
Poster Bd #
124
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Updated safety and clinical activity of durvalumab monotherapy in previously treated patients with stage IIIB/IV NSCLC.
First Author: Ani Sarkis Balmanoukian
Poster
2020 Genitourinary Cancers Symposium
An open-label, multicenter, phase IIIb study of patients with urinary tract carcinoma (UTC) (STRONG): Interim safety results for fixed-dose durvalumab (D) monotherapy (module A).
First Author: Guru Sonpavde
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Updated overall survival and safety profile of durvalumab monotherapy in advanced NSCLC.
First Author: Matthew D. Hellmann
Poster
2024 ASCO Annual Meeting
A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced NSCLC.
First Author: Chunjiao Wu